Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis

CONCLUSION: Combination of chidamide and envafolimab showed efficacy signals in certain NSCLC patients. But further identification of beneficial population is necessary for precision treatment.PMID:38597130 | DOI:10.1002/cam4.7175

Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: Yaxiong Zhang Zihong Chen Yu Liu Liang Han Wei Jiang Qiming Wang Jianhua Shi Liqin Lu Jianying Li Mingjun Zhang Yan Huang Yunpeng Yang Xue Hou Li Zhang Jing Li Wenfeng Fang Gang Chen Source Type: research